复方桃仁软肝胶囊联合拉米夫定治疗慢性乙型肝炎肝纤维化的临床观察

Therapeutic Effect of Lamivudine Combined with Compound Taoren Ruangan Capsules on Hepatic Fibrosis in Patients with Chronic Hepatitis B

目的:观察复方桃仁软肝胶囊联合拉米夫定抗乙型肝炎肝纤维化的疗效。方法:60例慢性乙型肝炎肝纤维化患者被随机分为复方桃仁软肝胶囊联合拉米夫定(治疗组)和单用拉米夫丁(对照组)，疗程为9mo。观察治疗前后两组患者血清肝纤维化指标:透明质酸酶(HA)、IV型胶原(IV-C)和层粘蛋白(LN)的变化。结果:治疗组治疗后血清肝纤维各项指标均显著改善，与对照组比较有统计学差异(P<0.01或P<0.05)。结论:复方桃仁软肝胶囊联合拉米夫定可能具有抗乙型肝炎肝纤维化的功效，可在临床进一步验证。

Objective： To observe the therapeutic effect of lamivudine combined with compound Taoren Ruangan capsules on hepatic fibrosis in patients with chronic hepatitis B. Methods： 60 patients with hepatic fibrosis of chronic hepatitis B were randomly divided into two groups. One group （involved 40 cases） treated with lamivudine combined with compound Taoren Ruangan capsules for 9 months, the other （involved 20 cases） treated with lamivudine for 9 months as control. After treatment, the markers of hepatic fibrosis were detected, Results： In the treatment group, HA, IV-C and LN were all significantly decreased from that of control group （P〈0.01）. Conclusion： These results show that the treatment of lamivudine combined with compound Taoren Ruangan capsules may be able to prevent hepatic fibrosis. It is suggested to be furture evaluated in the treatment of patients with chronic hepatitis B.